key: cord-0869631-8tga8nmg authors: Ghazvini, Kiarash; Keikha, Masoud title: Cure virologique, efficacité clinique et sécurité de la supplémentation en Remdesivir contre l'infection par le SRAS-CoV 2 ; preuves issues d'études sur l'homme date: 2020-10-06 journal: nan DOI: 10.1016/j.phclin.2020.08.007 sha: 9875f51b0e0bed39ffaecb2c15a66c13b8bae30a doc_id: 869631 cord_uid: 8tga8nmg nan illness which, in 5% of cases, develops into critical illness due to acute respiratory distress syndrome and respiratory failure [4] . There is no selective treatment for COVID-19, while the number of cases has reached 11,000,000 worldwide [5] . Remdesivir (GS-5734) is a monophosphoramidate prodrug which is a nucleoside analogue of adenosine triphosphate, initially developed to treat Ebola (filovirus) infection, but which shows, both in vitro and in vivo, inhibitory efficacy against paramyxoviruses, pneumoviruses and beta-coronaviruses (SARS-CoV 1 and MERS-CoV) [6] [7] [8] [9] . In addition, Pizzorno et al. showed that Remdesivir has inhibitory effects on SARS-CoV-2 replication in human nasal and bronchial epithelial cells [10] , and Williamson et al. confirmed potential inhibitory effects of SARS-CoV 2 in a rhesus macaque model ( Fig. 1 ) [11] . Numerous studies investigated the therapeutic effects of Remdesivir against SARS-CoV 2 [12] [13] [14] . The FDA confirmed efficacy in the US [13] [14] , but clinical findings are controversial [15] [16] . The aim of the present study was to assess the clinical efficacy and safety of Remdesivir in the treatment of COVID-19 patients, using human studies. We performed a search of the PubMed, Scopus, Cochrane library, Google Scholar, medRxiv and bioRxiv databases to obtain articles on the efficacy of Remdesivir in COVID-19. A systematic search was conducted up to July 2020 using MeSH terms such as "2019 novel coronavirus", "2019-nCoV", "COVID-19", "coronavirus disease 2019", and "Remdesivir". The title and abstract of retrieved articles were evaluated for relevance, and potentially relevant articles were reviewed in full-text to extract information on 1) first author, 2) country, 3) sample size, 4) mean age, 5) mortality, 6) number of adverse events, 7) Remdesivir doses, 8) the percentage of mechanically ventilated patients, and 9) number of references (Table I) . Data on virological cure (virus clearance on RT-PCR), improvement, hospital discharge, adverse events and death were used to measure event rates with 95% confidence intervals. We also Overall, we showed that Remdesivir was an efficient therapeutic agent against SARS-CoV 2; particularly, time to recovery was reduced compared placebo. Recently, after the first trials on 1,061 COVID-19 patients treated by Remdesivir, the NIH concluded that Remdesivir has clinical benefit for treatment and shortens time to recovery in SARS-CoV2 patients [24] . However, there remain 30 trials registered in the ClinicalTrials.gov database which need to enroll patients. In addition, there is bias in the current completed trials on the efficacy of Remdesivir against COVID-19; for example, Chinese trials investigated more severe COVID-19 patients; there is diversity in patient enrolment and in end-points; there are no control groups in case reports which investigated the efficacy of Remdesivir for COVID-19; and some trials showed no significant difference between Remdesivir and placebo groups [15] [16] 25] . WHO declares COVID-19 a pandemic Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study COVID-19 and therapeutic drugs repurposing in hand: the need for collaborative efforts Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. BioRxiv. 2020. Nature Information for Clinicians on Therapeutic Options for COVID-19 Patients Available A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 FDA grant remdesivir emergency use for COVID-19 after turbulent week Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Compassionate use of remdesivir for patients with severe Covid-19 First case of 2019 novel coronavirus in the United States First 12 patients with coronavirus disease 2019 (COVID-19) in the United States Clinical and virological data of the first cases of COVID-19 in Europe: a case series Delayed initiation of Remdesivir in a COVID-19-positive patient Remdesivir for the treatment of Covid-19-preliminary report Remdesivir for 5 or 10 days in patients with severe Covid-19 Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis Covid-19: Remdesivir is helpful but not a wonder drug, say researchers Remdesivir-Bringing Hope for COVID-19 Treatment